Abstract 19342: High-Sensitivity C-Reactive Protein Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) With and Without Stable Statin Therapy in Hypertriglyceridemic Patients With Metabolic Syndrome
Introduction: Elevated high-sensitivity C-reactive protein (hsCRP) is a marker for increased cardiovascular disease (CVD) risk. The metabolic syndrome (MetSyn) is a collection of CVD risk factors and includes high triglyceride (TG) levels as a diagnostic criterion. Statins reduce hsCRP. The combination of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) has not been shown to consistently lower hsCRP levels. Icosapent ethyl (IPE; formerly AMR101) is a high-purity prescription form of EPA ethyl ester approved to reduce TG levels in patients with severe (>=500 mg/dL) hypertriglyceridemia.
Hypothesis: We evaluated the relative hsCRP effects of IPE in patients with and without statin therapy among hypertriglyceridemic patients with MetSyn.
Methods: The MARINE study was a multicenter, placebo-controlled, double-blind, 12-week study of 229 randomized patients with TG >=500 and <=2000 mg/dL. This analysis evaluated the effect of IPE on hsCRP in a subset of patients from the MARINE study with MetSyn.
Results: The MARINE study included 204 patients from the intent-to-treat population with MetSyn. Compared to placebo, IPE 4 g/day significantly reduced blood levels of TG (35%; p<0.0001), non-high-density lipoprotein cholesterol (19.9%, p<0.0001), apo B (9.1%, p=0.0015), and hsCRP (40%, p=0.0007), without a significant increase in low-density lipoprotein cholesterol. IPE 4 g/day also reduced hsCRP levels by 27.6% (p=0.0385) and 78.0% (p=0.0035) compared to placebo in non-statin-treated (n=48) and statin-treated patients (n=16), respectively.
Conclusion: Compared to placebo, when administered to hypertriglyceridemic patients with MetSyn, IPE 4 g/day improved lipid levels and reduced hsCRP. Compared to placebo, IPE reduced hsCRP more in stable statin-treated patients than in those not treated with statins.
- © 2013 by American Heart Association, Inc.